Sunday, November 6, 2016

Alzheimer’s drug candidate trial data disclosed

BACE1 inhibitor verubecestat shows favorable side effect profile

via Chemical & Engineering News: Biological SCENE http://ift.tt/2fwnUiZ
Posted by at
Labels: ,

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)